Cadwalader allows sharing content.
Email to a friend or colleague:
From
To
Subject
Email Cadwalader is representing The Medicines Company (NASDAQ: MDCO), a provider of solutions in serious infectious disease care, acute cardiovascular care and surgery and perioperative care, in its agreement to divest three of its marketed cardiovascular products – Cleviprex® (clevidipine) injectable emulsion, Kengreal® (cangrelor) and rights to Argatroban® for Injection – and related assets to Chiesi Farmaceutici S.p.A., for up to $792 million, consisting of $260 million in cash payable at closing, up to $480 million in sales-based milestone payments, the assumption by Chiesi of up to $50 million in milestone payment obligations and approximately $2 million for product inventory. https://www.cadwalader.com/news/news-release/cadwalader-represents-the-medicines-company-in-agreement-to-divest-three-of-its-marketed-cardiovascular-products